SuperworthNexgel price to sales ratio NXGL
Market value divided by revenue over the last twelve months, since 2022.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 0.4×
- May 2026
- 5-year median
- 3.5×
- 5-year range
- 0.4× to 195×
- Peer median
- 1.4×
Nexgel's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in May 2026, at 0.4×.
On the days it had one over the last 5 years, its median was 3.5×, from 0.4× in Apr 2026 to 195× in Feb 2022.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.4× | 0.4× | 1.3× |
| 2025 | 1.1× | 1.1× | 3.9× |
| 2024 | 4.7× | 2.7× | 4.8× |
| 2023 | 3.4× | 2.9× | 6.6× |
| 2022 | 3.4× | 3.2× | 195× |
Against its peers
Companies in Healthcare nearest Nexgel's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| NXGLNexgel | n/m |
| OXBROXBRIDGE RE HOLDINGS | 2.8× |
| EDUCEducational Development | 0.4× |
| GTIMGood Times Restaurants | 0.1× |
| MDRRMedalist Diversified | 1.6× |
| BCGBinah Capital | 0.1× |
| VIPVulcan Infrastructure & Power | 0.4× |
| MXCMexco Energy | 3.0× |
| CKXCKX Lands | 31.0× |
| MSGMMotorsport Games | 1.5× |
| ATCHAtlasClear | 1.2× |
| Peer median | 1.4× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Nexgel
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.